Barclays Upgrades bluebird bio to Overweight, Raises Price Target to $8
Portfolio Pulse from richadhand@benzinga.com
Barclays analyst Gena Wang upgrades bluebird bio (NASDAQ:BLUE) from Equal-Weight to Overweight and raises the price target from $7 to $8.
June 01, 2023 | 9:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays upgrades bluebird bio to Overweight and raises the price target from $7 to $8.
The upgrade from Equal-Weight to Overweight by Barclays analyst Gena Wang indicates a positive outlook for bluebird bio. The raised price target from $7 to $8 also suggests an expected increase in the stock's value. This news is likely to have a positive short-term impact on BLUE's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100